Selected research
Industry Research
Granulomatosis with Polyangiitis Drug Industry Research Report 2026
Market perspective
The global Granulomatosis with Polyangiitis Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Granulomatosis with Polyangiitis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Granulomatosis with Polyangiitis Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Granulomatosis with Polyangiitis Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Granulomatosis with Polyangiitis Drug include Sandoz International GmbH, GlaxoSmithKline Plc, The International Biotechnology Center (IBC) Generium, Panacea Biotec Ltd, Iltoo Pharma, Genor BioPharma Co Ltd, Coherus BioSciences Inc, ChemoCentryx Inc and Bristol-Myers Squibb Company, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Granulomatosis with Polyangiitis Drug market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Granulomatosis with Polyangiitis Drug Market by Company
Sandoz International GmbH
GlaxoSmithKline Plc
The International Biotechnology Center (IBC) Generium
Panacea Biotec Ltd
Iltoo Pharma
Genor BioPharma Co Ltd
Coherus BioSciences Inc
ChemoCentryx Inc
Bristol-Myers Squibb Company
Bionovis SA
Granulomatosis with Polyangiitis Drug Segment by Type
Avacopan
Benralizumab
Rituximab Biosimilar
Others
Granulomatosis with Polyangiitis Drug Segment by Application
Hospital
Clinic
Others
Granulomatosis with Polyangiitis Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Granulomatosis with Polyangiitis Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Granulomatosis with Polyangiitis Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Granulomatosis with Polyangiitis Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Granulomatosis with Polyangiitis Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Granulomatosis with Polyangiitis Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Granulomatosis with Polyangiitis Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Avacopan
- Benralizumab
- Rituximab Biosimilar
- Others
Applications
- Hospital
- Clinic
- Others
Companies covered
- Sandoz International GmbH
- GlaxoSmithKline Plc
- The International Biotechnology Center (IBC) Generium
- Panacea Biotec Ltd
- Iltoo Pharma
- Genor BioPharma Co Ltd
- Coherus BioSciences Inc
- ChemoCentryx Inc
- Bristol-Myers Squibb Company
- Bionovis SA
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Granulomatosis with Polyangiitis Drug Market Size (2021-2032)
- 2.2.2 Global Granulomatosis with Polyangiitis Drug Sales (2021-2032)
- 2.2.3 Global Granulomatosis with Polyangiitis Drug Market Average Price (2021-2032)
- 2.3 Granulomatosis with Polyangiitis Drug by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Avacopan
- 2.3.3 Benralizumab
- 2.3.4 Rituximab Biosimilar
- 2.3.5 Others
- 2.4 Granulomatosis with Polyangiitis Drug by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Granulomatosis with Polyangiitis Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Granulomatosis with Polyangiitis Drug Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Granulomatosis with Polyangiitis Drug Revenue of Manufacturers (2021-2026)
- 3.4 Global Granulomatosis with Polyangiitis Drug Average Price by Manufacturers (2021-2026)
- 3.5 Global Granulomatosis with Polyangiitis Drug Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Granulomatosis with Polyangiitis Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Granulomatosis with Polyangiitis Drug, Product Type & Application
- 3.8 Global Manufacturers of Granulomatosis with Polyangiitis Drug, Established Date
- 3.9 Global Granulomatosis with Polyangiitis Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Sandoz International GmbH
- 4.1.1 Sandoz International GmbH Company Information
- 4.1.2 Sandoz International GmbH Business Overview
- 4.1.3 Sandoz International GmbH Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Sandoz International GmbH Granulomatosis with Polyangiitis Drug Product Portfolio
- 4.1.5 Sandoz International GmbH Recent Developments
- 4.2 GlaxoSmithKline Plc
- 4.2.1 GlaxoSmithKline Plc Company Information
- 4.2.2 GlaxoSmithKline Plc Business Overview
- 4.2.3 GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Product Portfolio
- 4.2.5 GlaxoSmithKline Plc Recent Developments
- 4.3 The International Biotechnology Center (IBC) Generium
- 4.3.1 The International Biotechnology Center (IBC) Generium Company Information
- 4.3.2 The International Biotechnology Center (IBC) Generium Business Overview
- 4.3.3 The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Product Portfolio
- 4.3.5 The International Biotechnology Center (IBC) Generium Recent Developments
- 4.4 Panacea Biotec Ltd
- 4.4.1 Panacea Biotec Ltd Company Information
- 4.4.2 Panacea Biotec Ltd Business Overview
- 4.4.3 Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Product Portfolio
- 4.4.5 Panacea Biotec Ltd Recent Developments
- 4.5 Iltoo Pharma
- 4.5.1 Iltoo Pharma Company Information
- 4.5.2 Iltoo Pharma Business Overview
- 4.5.3 Iltoo Pharma Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Iltoo Pharma Granulomatosis with Polyangiitis Drug Product Portfolio
- 4.5.5 Iltoo Pharma Recent Developments
- 4.6 Genor BioPharma Co Ltd
- 4.6.1 Genor BioPharma Co Ltd Company Information
- 4.6.2 Genor BioPharma Co Ltd Business Overview
- 4.6.3 Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Product Portfolio
- 4.6.5 Genor BioPharma Co Ltd Recent Developments
- 4.7 Coherus BioSciences Inc
- 4.7.1 Coherus BioSciences Inc Company Information
- 4.7.2 Coherus BioSciences Inc Business Overview
- 4.7.3 Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Product Portfolio
- 4.7.5 Coherus BioSciences Inc Recent Developments
- 4.8 ChemoCentryx Inc
- 4.8.1 ChemoCentryx Inc Company Information
- 4.8.2 ChemoCentryx Inc Business Overview
- 4.8.3 ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Product Portfolio
- 4.8.5 ChemoCentryx Inc Recent Developments
- 4.9 Bristol-Myers Squibb Company
- 4.9.1 Bristol-Myers Squibb Company Company Information
- 4.9.2 Bristol-Myers Squibb Company Business Overview
- 4.9.3 Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Product Portfolio
- 4.9.5 Bristol-Myers Squibb Company Recent Developments
- 4.10 Bionovis SA
- 4.10.1 Bionovis SA Company Information
- 4.10.2 Bionovis SA Business Overview
- 4.10.3 Bionovis SA Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Bionovis SA Granulomatosis with Polyangiitis Drug Product Portfolio
- 4.10.5 Bionovis SA Recent Developments
5 Global Granulomatosis with Polyangiitis Drug Market Scenario by Region
- 5.1 Global Granulomatosis with Polyangiitis Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Granulomatosis with Polyangiitis Drug Sales by Region: 2021-2032
- 5.2.1 Global Granulomatosis with Polyangiitis Drug Sales by Region: 2021-2026
- 5.2.2 Global Granulomatosis with Polyangiitis Drug Sales by Region: 2027-2032
- 5.3 Global Granulomatosis with Polyangiitis Drug Revenue by Region: 2021-2032
- 5.3.1 Global Granulomatosis with Polyangiitis Drug Revenue by Region: 2021-2026
- 5.3.2 Global Granulomatosis with Polyangiitis Drug Revenue by Region: 2027-2032
- 5.4 North America Granulomatosis with Polyangiitis Drug Market Facts & Figures by Country
- 5.4.1 North America Granulomatosis with Polyangiitis Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Granulomatosis with Polyangiitis Drug Sales by Country (2021-2032)
- 5.4.3 North America Granulomatosis with Polyangiitis Drug Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Granulomatosis with Polyangiitis Drug Market Facts & Figures by Country
- 5.5.1 Europe Granulomatosis with Polyangiitis Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Granulomatosis with Polyangiitis Drug Sales by Country (2021-2032)
- 5.5.3 Europe Granulomatosis with Polyangiitis Drug Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Granulomatosis with Polyangiitis Drug Market Facts & Figures by Country
- 5.6.1 Asia Pacific Granulomatosis with Polyangiitis Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Granulomatosis with Polyangiitis Drug Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Granulomatosis with Polyangiitis Drug Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Granulomatosis with Polyangiitis Drug Market Facts & Figures by Country
- 5.7.1 South America Granulomatosis with Polyangiitis Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Granulomatosis with Polyangiitis Drug Sales by Country (2021-2032)
- 5.7.3 South America Granulomatosis with Polyangiitis Drug Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Granulomatosis with Polyangiitis Drug Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Granulomatosis with Polyangiitis Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Granulomatosis with Polyangiitis Drug Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Granulomatosis with Polyangiitis Drug Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Granulomatosis with Polyangiitis Drug Sales by Type (2021-2032)
- 6.1.1 Global Granulomatosis with Polyangiitis Drug Sales by Type (2021-2032) & (W Units)
- 6.1.2 Global Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2021-2032)
- 6.2 Global Granulomatosis with Polyangiitis Drug Revenue by Type (2021-2032)
- 6.2.1 Global Granulomatosis with Polyangiitis Drug Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Type (2021-2032)
- 6.3 Global Granulomatosis with Polyangiitis Drug Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Granulomatosis with Polyangiitis Drug Sales by Application (2021-2032)
- 7.1.1 Global Granulomatosis with Polyangiitis Drug Sales by Application (2021-2032) & (W Units)
- 7.1.2 Global Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2021-2032)
- 7.2 Global Granulomatosis with Polyangiitis Drug Revenue by Application (2021-2032)
- 7.2.1 Global Granulomatosis with Polyangiitis Drug Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Application (2021-2032)
- 7.3 Global Granulomatosis with Polyangiitis Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Granulomatosis with Polyangiitis Drug Value Chain Analysis
- 8.1.1 Granulomatosis with Polyangiitis Drug Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Granulomatosis with Polyangiitis Drug Production Mode & Process
- 8.2 Granulomatosis with Polyangiitis Drug Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Granulomatosis with Polyangiitis Drug Distributors
- 8.2.3 Granulomatosis with Polyangiitis Drug Customers
9 Global Granulomatosis with Polyangiitis Drug Analyzing Market Dynamics
- 9.1 Granulomatosis with Polyangiitis Drug Industry Trends
- 9.2 Granulomatosis with Polyangiitis Drug Industry Drivers
- 9.3 Granulomatosis with Polyangiitis Drug Industry Opportunities and Challenges
- 9.4 Granulomatosis with Polyangiitis Drug Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst